ClinicalTrials.Veeva

Menu

Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

S

Skingenix

Status and phase

Enrolling
Phase 2

Conditions

Burns

Treatments

Drug: Investigational Drug, MW-III
Drug: Silvadene® Cream 1% [Silver Sulfadiazine]

Study type

Interventional

Funder types

Industry

Identifiers

NCT01297400
MW-III-BURN-2-001

Details and patient eligibility

About

To compare MW-III to Silvadene® Cream 1% (Silver Sulfadiazine) with respect to "time to healing" (≥95% re-epithelialization) of a partial thickness target thermal burn.

Full description

This phase 2 pilot study will assess the safety and efficacy of topical MW-III on thermal burns.

Enrollment

60 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Adults, 18 years of age or older on the day of signing the informed consent.
  2. Thermal Burns not exceeding a total body surface area (TBSA) OF 25%, with at least one partial thickness burn of 0.5% TBSA or greater. If full thickness burn(s) are present at screening, the total full thickness burn area shall not exceed 10% TBSA. Note: TBSA excludes areas of superficial (first degree) burns.
  3. Able and willing to give informed consent and comply with study procedures.

Exclusion criteria

  1. Any burn that at screening is:

    1. infected.
    2. circumferential or deemed, in the judgment of the investigator, at high risk for developing compartment syndrome.
    3. partial thickness that is likely, in the judgment of the Investigator, to require grafting within 72 hours, or other non-protocol intervention.
  2. Severe inhalation injury or other significant non-burn trauma.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

60 participants in 2 patient groups

Investigational Drug, MW-III
Experimental group
Description:
Investigational Drug, MW-III
Treatment:
Drug: Investigational Drug, MW-III
Standard of care
Active Comparator group
Description:
Silvadene® Cream 1% \[Silver Sulfadiazine\]
Treatment:
Drug: Silvadene® Cream 1% [Silver Sulfadiazine]

Trial contacts and locations

6

Loading...

Central trial contact

Eric Wang, MD; Vicki Christodoulou, MS, JD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems